贝那普利联合阿托伐他汀在2型糖尿病并发肾病患者中的疗效观察
详细信息 查看官网全文
- 论文作者：李海明
- 年：2016
- 作者机构：陕西省府谷县人民医院;
- 论文关键词：贝那普利 ; 阿托伐他汀 ; 2型糖尿病并发肾病患者 ; 疗效
- 英文论文关键词：that split ; Atorvastatin ; In patients with type 2 diabetes mellitus complicated with kidney disease ; The curative effect
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R587.2;R692.9
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：2
- 文件大小：2027k
- 原文格式：D
- 会议级别：全国
摘要
目的:研究贝那普利联合阿托伐他汀在2型糖尿病并发肾病患者中的疗效。方法:病例资料来源于我院2011年2月-2015年10月就诊的100例2型糖尿病并发肾病患者。根据密封信封不透光法分组,100例患者分为B组和B+A组。所有患者给予常规降糖治疗,B组加用贝那普利;B+A组加用贝那普利联合阿托伐他汀治疗。比较(1)总有效率;(2)副作用;(3)干预前和干预后患者尿白蛋白/肌酐、尿蛋白排泄率、C反应蛋白、糖化血红蛋白的差异。结果:(1)B+A组对比B组总有效率更高,P<0.05;(2)B+A组、B组副作用接近,P>0.05;(3)干预前两组尿白蛋白/肌酐、尿蛋白排泄率、C反应蛋白、糖化血红蛋白相似,P>0.05;干预后B+A组对比B组尿白蛋白/肌酐、尿蛋白排泄率、C反应蛋白、糖化血红蛋白改善更显著,P<0.05。结论:贝那普利联合阿托伐他汀在2型糖尿病并发肾病患者中的疗效确切,可有效改善患者血糖水平和肾功能,安全性高,值得推广。
objective: to study the bay that split joint atorvastatin in patients with type 2 diabetes mellitus complicated with kidney disease curative effect. Methods: the clinical data fromour hospital in February 2014- October 2015 of 100 patients with type 2 diabetes mellitus complicated with kidney disease. According to seal the envelope not pervious to light grouping approach, 100 patients were divided into group A and B + B group. All patients were given routine hypoglycemic therapy, group B with Mr That split; And B + A group from the split joint atorvastatin treatment.(1) thetotal effective rate;(2) side effects;(3) the intervention before and after intervention in patients with urinary albumin/creatinine, urine protein excretion rate, the difference between c-reactive protein andglycated hemoglobin. Results:(1) compared with group B B + A group total effective rate is higher, P < 0.05;(2) + B group A and group B side close, P > 0.05;(3) the intervention in the first two groupof urinary albumin/creatinine, urine protein excretion rate, c-reactive protein and glycated hemoglobin, P > 0.05; B + A group after the intervention compared with group B urinary albumin/creatinine, urine protein excretion rate, c-reactive protein and glycated hemoglobin improved more significantly, P < 0.05). Conclusion: Mr That split joint atorvastatin in patients with type 2 diabetes mellituscomplicated with kidney disease curative effect, can effectively improve the patients' blood sugar levels and renal function, high safety, is worth promoting.
objective: to study the bay that split joint atorvastatin in patients with type 2 diabetes mellitus complicated with kidney disease curative effect. Methods: the clinical data fromour hospital in February 2014- October 2015 of 100 patients with type 2 diabetes mellitus complicated with kidney disease. According to seal the envelope not pervious to light grouping approach, 100 patients were divided into group A and B + B group. All patients were given routine hypoglycemic therapy, group B with Mr That split; And B + A group from the split joint atorvastatin treatment.(1) thetotal effective rate;(2) side effects;(3) the intervention before and after intervention in patients with urinary albumin/creatinine, urine protein excretion rate, the difference between c-reactive protein andglycated hemoglobin. Results:(1) compared with group B B + A group total effective rate is higher, P < 0.05;(2) + B group A and group B side close, P > 0.05;(3) the intervention in the first two groupof urinary albumin/creatinine, urine protein excretion rate, c-reactive protein and glycated hemoglobin, P > 0.05; B + A group after the intervention compared with group B urinary albumin/creatinine, urine protein excretion rate, c-reactive protein and glycated hemoglobin improved more significantly, P < 0.05). Conclusion: Mr That split joint atorvastatin in patients with type 2 diabetes mellituscomplicated with kidney disease curative effect, can effectively improve the patients' blood sugar levels and renal function, high safety, is worth promoting.
引文
[1]贺宏斌.贝那普利和阿托伐他汀联用对2型糖尿病并发肾病的治疗效果研究[J].中国实用医刊,2015,24(14):93-95.
[2]谭小梅.贝那普利联合阿托伐他汀在2型糖尿病并发肾病患者治疗中的临床价值[J].医药前沿,2016,6(2):211-212.
[3]禹亚丽.贝那普利和阿托伐他汀联用对2型糖尿病并发肾病的治疗效果研究[J].中外医学研究,2013,12(22):57-57.
[4]孙世荣.贝那普利和阿托伐他汀联用对2型糖尿病并发肾病疗效观察[J].中国卫生标准管理,2016,7(5):96-97.
[5]王强,邓晓风,周莹等.盐酸贝那普利辅助治疗早期糖尿病肾病56例疗效观察[J].中国医药指南,2014,14(4):38-39.
[6]王祯江,王志莲,何春桐等.贝那普利和阿托伐他丁联合用药对2型糖尿病并发肾病的治疗效果观察[J].医药前沿,2016,6(9):132-133.
[7]喻明书.贝那普利联合阿托伐他汀钙治疗原发性高血压伴高血脂的临床观察[J].浙江临床医学,2011,13(4):371-373.
[8]车玫,杜国峰,张志敏等.阿托伐他汀联合贝那普利、氨氯地平对高血压患者动态动脉硬化指数及肾功能的影响[J].山东医药,2014,24(45):30-32.
[2]谭小梅.贝那普利联合阿托伐他汀在2型糖尿病并发肾病患者治疗中的临床价值[J].医药前沿,2016,6(2):211-212.
[3]禹亚丽.贝那普利和阿托伐他汀联用对2型糖尿病并发肾病的治疗效果研究[J].中外医学研究,2013,12(22):57-57.
[4]孙世荣.贝那普利和阿托伐他汀联用对2型糖尿病并发肾病疗效观察[J].中国卫生标准管理,2016,7(5):96-97.
[5]王强,邓晓风,周莹等.盐酸贝那普利辅助治疗早期糖尿病肾病56例疗效观察[J].中国医药指南,2014,14(4):38-39.
[6]王祯江,王志莲,何春桐等.贝那普利和阿托伐他丁联合用药对2型糖尿病并发肾病的治疗效果观察[J].医药前沿,2016,6(9):132-133.
[7]喻明书.贝那普利联合阿托伐他汀钙治疗原发性高血压伴高血脂的临床观察[J].浙江临床医学,2011,13(4):371-373.
[8]车玫,杜国峰,张志敏等.阿托伐他汀联合贝那普利、氨氯地平对高血压患者动态动脉硬化指数及肾功能的影响[J].山东医药,2014,24(45):30-32.